In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies
Abstract
OBJECTIVES: To investigate the in vitro activity of olorofim (F901318), a novel broad-spectrum antifungal agent, against 150 strains belonging to 16 different cryptic species of Aspergillus by EUCAST and CLSI methodologies. METHODS: Olorofim, amphotericin B, micafungin, posaconazole and voriconazole were tested against cryptic species belonging to Aspergillus fumigatus complex (n = 57), Aspergillus ustus complex (n = 25), Aspergillus niger complex (n = 20), Aspergillus flavus complex (n = 20), Aspergillus circumdati complex (n = 15) and Aspergillus terreus complex (n = 13) using EUCAST and CLSI methodologies for broth microdilution susceptibility testing of antifungal agents. RESULTS: Olorofim was the only drug with activity against all cryptic species of Aspergillus tested, including the multiresistant species Aspergillus lentulus, Aspergillus fumigatiaffinis and Aspergillus calidoustus. Geometric means of MICs for olorofim were lower (0.017, 0.015 and 0.098 mg/L, respectively, for EUCAST; and 0.015, 0.015 and 0.048 mg/L, respectively, for CLSI) than for amphotericin B (4.438, 12.699 and 0.554 mg/L, respectively, for EUCAST; and 0.758, 1.320 and 0.447 mg/L, respectively, for CLSI), voriconazole (2.549, 2.297 and 5.856 mg/L, respectively, for EUCAST; and 2.071, 1.741 and 5.657 mg/L, respectively, for CLSI) and posaconazole (0.307, 0.308 and 12.996 mg/L, respectively, for EUCAST; and 0.391, 0.215 and 9.514 mg/L, respectively, for CLSI). CONCLUSIONS: Olorofim shows encouraging in vitro activity against cryptic species of Aspergillus that can be hard to treat with current antifungal therapies. Further studies are warranted in order to assess its efficacy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Olorofim lacks activity against Mucorales species and Exophiala dermatitidis due to phylogenetically different DHODH target enzymes.
“It is important to note this drug lacks activity against Mucorales species or Exophiala dermatitidis due to phylogenetically different DHODH target enzymes [63, 65].”
From Investigational Agents for the Treatment of Resistant Yeasts and Molds (2021) · cites this paper as [65]
Cites
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926 · see citing works
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608 · see citing works
Aspergillus species identification in the clinical setting
Balajee, S. A., Houbraken, J. A. M. P., Verweij, P. E., et al. (2007) · Studies in Mycology · doi:10.3114/sim.2007.59.05 · Cited by 305 · see citing works
Balajee, S. A., Kano, R., Baddley, J. W., Moser, S. A., Marr, K. A., Alexander, B. D., Andes, D. R., Kontoyiannis, D. P., Perrone, G., Peterson, S., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01070-09 · Cited by 302 · see citing works
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289 · see citing works
Population-Based Survey of Filamentous Fungi and Antifungal Resistance in Spain (FILPOP Study)
Alastruey-Izquierdo, A., Mellado, E., Peláez, T., Pemán, J., Zapico, S., Alvarez, M., Rodríguez-Tudela, J. L., Cuenca-Estrella, M., & FILPOP Study Group (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00383-13 · Cited by 276 · see citing works
Self-citationAspergillus Section Fumigati : Antifungal Susceptibility Patterns and Sequence-Based Identification
Alcázar‐Fuoli, L., Mellado, E., Alastruey‐Izquierdo, A., Cuenca‐Estrella, M., & Rodrı́guez-Tudela, J. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00942-07 · Cited by 260 · see citing works
Self-citationPfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N., & Castanheira, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00308-13 · Cited by 237 · see citing works
Baddley, J. W., Marr, K. A., Andes, D. R., Walsh, T. J., Kauffman, C. A., Kontoyiannis, D. P., Ito, J. I., Balajee, S. A., Pappas, P. G., & Moser, S. A. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00854-09 · Cited by 190 · see citing works
Antifungal Susceptibility Profile of Cryptic Species of Aspergillus
Alastruey‐Izquierdo, A., Alcázar‐Fuoli, L., & Cuenca‐Estrella, M. (2014) · Mycopathologia · doi:10.1007/s11046-014-9775-z · Cited by 138 · see citing works
Self-citationBuil, J. B., Rijs, A. J. M. M., Meis, J. F. G. M., Birch, M., Law, D., Melchers, W. J. G., & Verweij, P. E. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx177 · Cited by 100 · see citing works
Negri, C. E., Gonçalves, S. S., Xafranski, H., Bergamasco, M. D., Aquino, V. R., Castro, P. T. O., & Colombo, A. L. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01582-14 · Cited by 92 · see citing works
Wiederhold, N. P., Law, D., & Birch, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx065 · Cited by 85 · see citing works
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Birch, M., Law, D., Rex, J. H., Catano, G., & Patterson, T. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-18 · Cited by 80 · see citing works
Jørgensen, K. M., Astvad, K. M. T., Hare, R. K., & Arendrup, M. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00487-18 · Cited by 75 · see citing works
Biswas, C., Law, D., Birch, M., Halliday, C. L., Sorrell, T. C., Rex, J. H., Slavin, M. A., & Chen, S. C. ‐. (2017) · Medical Mycology · doi:10.1093/mmy/myx161 · Cited by 66 · see citing works
Negri, C. E., Johnson, A., McEntee, L., Box, H., Whalley, S., Schwartz, J. A., Ramos-Martin, V., Livermore, J., Kolamunnage‐Dona, R., Colombo, A. L., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix479 · Cited by 59 · see citing works
Cuenca‐Estrella, M., & Rodrı́guez-Tudela, J. L. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.2 · Cited by 56 · see citing works
Self-citationTreatment of Infections by Cryptic Aspergillus Species
Nedel, W. L., & Pasqualotto, A. C. (2014) · Mycopathologia · doi:10.1007/s11046-014-9811-z · Cited by 24 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467 · see citing works
Aspiring Antifungals: Review of Current Antifungal Pipeline Developments
Gintjee, T., Donnelley, M., & Thompson, G. (2020) · Journal of Fungi · doi:10.3390/jof6010028 · Cited by 225 · see citing works
Development and research progress of anti-drug resistant fungal drugs
Cui, X., Wang, L., Lü, Y., & Yue, C. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.004 · Cited by 85 · see citing works
Investigational Agents for the Treatment of Resistant Yeasts and Molds
Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32 · see citing works
- Authors
- Rivero-Menendez, O., Cuenca-Estrella, M., & Alastruey-Izquierdo, A.
- Affiliations
- Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; Spanish Network for the Research in Infectious Diseases (REIPI RD16/CIII/0004/0003), Instituto de Salud Carlos III, Madrid, Spain
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03-19
- Volume
- 74
- Issue
- 6
- Pages
- 1586-1590
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2924833782
- Cited by
- 66
- References
- 19
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 6 · 2022: 12 · 2021: 18 · 2020: 10 · 2019: 3
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fondo de Investigación Sanitaria (FI14CIII/00025, PI13/02145, PI16CIII/00035)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- olorofim, Aspergillus, cryptic species, antifungal susceptibility, minimum inhibitory concentration, Aspergillus lentulus, Aspergillus calidoustus, amphotericin B, micafungin, posaconazole, voriconazole, antifungal resistance, EUCAST
- MeSH terms
- Acetamides, Antifungal Agents, Aspergillus, Microbial Sensitivity Tests, Piperazines, Pyrimidines, Pyrroles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
